{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"676","value":"1310"},{"groupId":"OG001","spread":"597","value":"1340"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Apparent volume of distribution, unadjusted for bioavailability (Vz/F) following a single dose of avapritinib","dispersionType":"Standard Error","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEAN","populationDescription":"Patients enrolled in Part 1 and Part 2 with a starting dose of 300 or 400 mg QD and available PK samples","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Apparent Volume of Distribution, Unadjusted for Bioavailability (Vz/F)","type":"SECONDARY","unitOfMeasure":"L"}